BRCA1 pathogenic variants

About

Gene context: BRCA1

Biomarker Type: Germline Variant

Present: True

Chromosome: 17

Requires Pathogenic: True

Legacy biomarker representation, assumes GRCh37 / hg19 genome build.

Mappings

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (2) FDA (2) HSE (1)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
EMA (1) HSE (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone